Jessica E. Burchette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jessica E. Burchette has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- David B. Cluck
Department of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy Johnson City Tennessee USA
3 shared publications - Kelly Covert
Department of Pharmacy Practice, East Tennessee State University Bill Gatton College of Pharmacy, Johnson City, TN, USA
2 shared publications Brett Tyler Morgan
Department of Family Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN
1 shared publicationBryan P. White
University of Oklahoma Medical Center, Oklahoma City, OK, USA
1 shared publication- Daniel B. Chastain
University of Georgia College of Pharmacy
1 shared publication G. Douglas Campbell
Division of Pulmonary, Critical Care and Sleep Medicine, University of Mississippi School of Medicine, Jackson, Mississippi; G.V. (Sonny) Montgomery Veterans Affairs Medical Center, Jackson, Mississippi
1 shared publication
Latest Publications
- 24 April 2026
- Published by Elsevier
Ciprofloxacin
- 5 November 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (4) , 378-393
Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder
Objective: To summarize the Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates and data for novel therapies/interventions. Data sources: Articles gathered from MEDLINE, Cochrane Reviews, and PubMed databases. Package inserts for novel agents were utilized. Search terms included chronic obstructive pulmonary disorder (COPD), inhaled corticosteroids (ICS), inhaled long-acting muscarinic antagonists (LAMA), inhaled long-acting beta-2 agonists (LABA), dupilumab, ensifentrine, icenticaftor, and itepekimab. Study selection and data extraction: English-language primary literature and review articles evaluated. GOLD guidelines from 2001 to 2025 were utilized. Data synthesis: Six meta-analyses and one randomized controlled trial (RCT) favor initial LAMA/LABA combination over monocomponent agents. Three RCTs note increased ICS efficacy with blood eosinophils >300 cells/µL. One meta-analysis and 8 RCTs address vaccinations, specifically RSV and pneumococcal. Novel medications ensifentrine, dupilumab, and icenticaftor each have 2 RCTs in patients with persistent symptoms despite optimized LAMA/LABA and ICS. Itepekimab is in phase 3 studies. The CAPTURE tool has 2 RCTs validating screening patients with unrecognized COPD. Relevance to patient care and clinical practice: Identification of notable changes to optimal COPD management, including LABA/LAMA therapy, judicious ICS use, updated vaccine recommendations, and potential roles for ensifentrine and dupilumab. Conclusion and Relevance: Evidence supports LABA/LAMA with nuanced use of ICS. Several novel therapies are approved or are being studied for patients suboptimally controlled. Pharmacists can assist in medication optimization and access; however, patient-specific factors like exacerbation history, blood eosinophils, and COPD endotype must be considered. Implementing early identification screening tools such as CAPTURE should factor into patient assessment.
- 5 November 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (4) , 378-393
Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder
Objective: To summarize the Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates and data for novel therapies/interventions. Data sources: Articles gathered from MEDLINE, Cochrane Reviews, and PubMed databases. Package inserts for novel agents were utilized. Search terms included chronic obstructive pulmonary disorder (COPD), inhaled corticosteroids (ICS), inhaled long-acting muscarinic antagonists (LAMA), inhaled long-acting beta-2 agonists (LABA), dupilumab, ensifentrine, icenticaftor, and itepekimab. Study selection and data extraction: English-language primary literature and review articles evaluated. GOLD guidelines from 2001 to 2025 were utilized. Data synthesis: Six meta-analyses and one randomized controlled trial (RCT) favor initial LAMA/LABA combination over monocomponent agents. Three RCTs note increased ICS efficacy with blood eosinophils >300 cells/µL. One meta-analysis and 8 RCTs address vaccinations, specifically RSV and pneumococcal. Novel medications ensifentrine, dupilumab, and icenticaftor each have 2 RCTs in patients with persistent symptoms despite optimized LAMA/LABA and ICS. Itepekimab is in phase 3 studies. The CAPTURE tool has 2 RCTs validating screening patients with unrecognized COPD. Relevance to patient care and clinical practice: Identification of notable changes to optimal COPD management, including LABA/LAMA therapy, judicious ICS use, updated vaccine recommendations, and potential roles for ensifentrine and dupilumab. Conclusion and Relevance: Evidence supports LABA/LAMA with nuanced use of ICS. Several novel therapies are approved or are being studied for patients suboptimally controlled. Pharmacists can assist in medication optimization and access; however, patient-specific factors like exacerbation history, blood eosinophils, and COPD endotype must be considered. Implementing early identification screening tools such as CAPTURE should factor into patient assessment.
- 7 December 2024
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (8) , 743-757
Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review
Objective: To review the evidence and discuss use of pivmecillinam in uncomplicated acute cystitis. Data sources: A literature search was conducted utilizing PubMed (from 2000 through August 2024) and ClinicalTrials.gov. Medical Subject Headings (MeSH) terms, such as mecillinam or pivmecillinam and urinary tract infections, were utilized. Additional references were identified by reviewing literature citations. Study selection and data extraction: Articles were limited to English language publications evaluating the efficacy or safety of pivmecillinam for urinary tract infections (UTIs) in adult populations. Data synthesis: Data from 6 randomized controlled trials support pivmecillinam for acute uncomplicated cystitis at doses of 200 to 400 mg 3 times daily for 3 to 7 days, with more consistent clinical and bacteriologic cure observed with 400 mg doses and longer therapy durations. Clinical evaluation of 400 mg 2 to 3 times daily is available with use more common in non–US Food and Drug Administration (FDA)-approved populations, such as men, pregnancy, and multidrug resistant infections. There are limited data supporting pivmecillinam for pyelonephritis; routine use is cautioned until further clinical data are available. Relevance to patient care and clinical practice in comparison with existing drugs: As resistance to first-line antimicrobials rises, the need for safe and effective treatment options remains high. Pivmecillinam represents a new therapeutic option available in the United States for outpatient management of uncomplicated acute cystitis. Conclusion: Pivmecillinam could be a key agent for uncomplicated acute cystitis. Utilization will likely be cost driven, but the promise of low resistance encourages the place in therapy when other agents are not susceptible to infecting uropathogens.
- 7 December 2024
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (8) , 743-757
Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review
Objective: To review the evidence and discuss use of pivmecillinam in uncomplicated acute cystitis. Data sources: A literature search was conducted utilizing PubMed (from 2000 through August 2024) and ClinicalTrials.gov. Medical Subject Headings (MeSH) terms, such as mecillinam or pivmecillinam and urinary tract infections, were utilized. Additional references were identified by reviewing literature citations. Study selection and data extraction: Articles were limited to English language publications evaluating the efficacy or safety of pivmecillinam for urinary tract infections (UTIs) in adult populations. Data synthesis: Data from 6 randomized controlled trials support pivmecillinam for acute uncomplicated cystitis at doses of 200 to 400 mg 3 times daily for 3 to 7 days, with more consistent clinical and bacteriologic cure observed with 400 mg doses and longer therapy durations. Clinical evaluation of 400 mg 2 to 3 times daily is available with use more common in non–US Food and Drug Administration (FDA)-approved populations, such as men, pregnancy, and multidrug resistant infections. There are limited data supporting pivmecillinam for pyelonephritis; routine use is cautioned until further clinical data are available. Relevance to patient care and clinical practice in comparison with existing drugs: As resistance to first-line antimicrobials rises, the need for safe and effective treatment options remains high. Pivmecillinam represents a new therapeutic option available in the United States for outpatient management of uncomplicated acute cystitis. Conclusion: Pivmecillinam could be a key agent for uncomplicated acute cystitis. Utilization will likely be cost driven, but the promise of low resistance encourages the place in therapy when other agents are not susceptible to infecting uropathogens.
- 29 July 2019
- Published by Aurora Health Care, Inc. in Journal of Patient-Centered Research and Reviews
- Vol. 6 (3) , 210-215
Relationship of Patient Self-Administered COPD Assessment Test to Physician Standard Assessment of Chronic Obstructive Pulmonary Disease in a Family Medicine Residency Training Program
Assessing the global impact of chronic obstructive pulmonary disease (COPD) on a patient’s life can be difficult to perform in the clinical setting due to time constraints and workflow challenges. The primary objective of this study was to compare disease impact ratings between patient self-administered COPD Assessment Test (CAT) and physician standard office assessment. This prospective study was conducted at a family medicine residency clinic in northeast Tennessee. The study included two study groups: 1) adult patients seen at the clinic during the 3-month study period with an active diagnosis of COPD, and 2) their physicians. Physicians’ assessment of the impact of COPD on their patients’ daily lives was compared to patients’ self-administered CAT assessments. Physician assessment of COPD impact and patient assessment of CAT categories significantly differed (χ2 = 11.0, P = 0.012). There was very poor agreement between patient and physician ratings (κ = 0.003), with 42.9% of physician ratings underestimating the impact, 28.6% overestimating the impact, and 28.6% correctly estimating the impact COPD had on their patients’ lives. These findings support the use of validated assessment tools to help providers understand the symptom burden for patients with COPD.
- 29 July 2019
- Published by Aurora Health Care, Inc. in Journal of Patient-Centered Research and Reviews
- Vol. 6 (3) , 210-215
Relationship of Patient Self-Administered COPD Assessment Test to Physician Standard Assessment of Chronic Obstructive Pulmonary Disease in a Family Medicine Residency Training Program
Assessing the global impact of chronic obstructive pulmonary disease (COPD) on a patient’s life can be difficult to perform in the clinical setting due to time constraints and workflow challenges. The primary objective of this study was to compare disease impact ratings between patient self-administered COPD Assessment Test (CAT) and physician standard office assessment. This prospective study was conducted at a family medicine residency clinic in northeast Tennessee. The study included two study groups: 1) adult patients seen at the clinic during the 3-month study period with an active diagnosis of COPD, and 2) their physicians. Physicians’ assessment of the impact of COPD on their patients’ daily lives was compared to patients’ self-administered CAT assessments. Physician assessment of COPD impact and patient assessment of CAT categories significantly differed (χ2 = 11.0, P = 0.012). There was very poor agreement between patient and physician ratings (κ = 0.003), with 42.9% of physician ratings underestimating the impact, 28.6% overestimating the impact, and 28.6% correctly estimating the impact COPD had on their patients’ lives. These findings support the use of validated assessment tools to help providers understand the symptom burden for patients with COPD.
- 1 July 2018
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 10 (7) , 834-841
Comparison of perceived personality traits between the pharmacy residents admitted through the match or scramble process
- 1 July 2018
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 10 (7) , 834-841
Comparison of perceived personality traits between the pharmacy residents admitted through the match or scramble process
- 22 July 2016
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 353 (1) , 31-40
Preventing Hospitalizations From Acute Exacerbations of Chronic Obstructive Pulmonary Disease
- 22 July 2016
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 353 (1) , 31-40
Preventing Hospitalizations From Acute Exacerbations of Chronic Obstructive Pulmonary Disease